Lincoln Pharmaceuticals Ltd (LINCOLN) — Announcement | 24 September 2026 (2 announcements)

24 September 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

1Announcement🔴 High Importance Neutral📄 PDF

📢 Key Event

Appointment of Pradeep Kumar Yadav as Senior General Manager-Quality Assurance

🔄 What Changed

Designation as Senior Management Personnel under SEBI LODR Schedule III

💡 Investor Takeaway

This management addition strengthens quality oversight but adds no immediate financial impact or guidance for investors.

Lincoln Pharmaceuticals announced the appointment of Pradeep Kumar Yadav as Senior General Manager-Quality Assurance effective September 24, 2026, designating him as Senior Management Personnel under SEBI LODR Regulation 30. The filing details his 20-year pharmaceutical quality expertise, international regulatory experience, and compliance obligations regarding service terms and performance expectations.

2Announcement🔴 High Importance Neutral📄 PDF

📢 Key Event

Resignation of Head of QA effective September 24, 2026

💡 Investor Takeaway

This leadership change may temporarily affect quality oversight but the company assures no disruption to operations.

Lincoln Pharmaceuticals announced the resignation of Mr. Manoj Rai, Sr. General Manager- QA (Head QA), effective September 24, 2026, after close of business hours, due to personal reasons. The filing complies with SEBI LODR Regulation 30 requirements and includes his resignation letter as Annexure A. The company confirmed his departure will not disrupt operations, with leadership transition plans underway to ensure continuity in quality assurance functions.

📊 Stock Analysis — LINCOLN ✨ Ask AI About This

About Lincoln Pharmaceuticals Ltd (LINCOLN)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹1,174.34 CrP/E: 12.2ROE: 12.7%ROCE: 16.9%Div Yield: 0.31%

View full LINCOLN stock details →

📡 Get AI alerts when LINCOLN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LINCOLN — Free

💡 Ask AI about this filing

"How does Yadav's quality background affect product approval timelines?""What specific performance metrics will evaluate his tenure?""How does this appointment compare to peer company quality leadership hires?"

Ask AI Free →

📊 More LINCOLN filings

Announcement — 23 September 2026Lincoln Pharmaceuticals has announced that its trading window will close on October 1, 2026, and rem...
🔴 Annual Report — 5 September 2026Lincoln Pharmaceuticals reported FY2025-26 revenue of **₹671.03 crores**, EBITDA of **[amount contex...
🟡 Board Meeting — 5 September 2026Lincoln Pharmaceuticals announced its 32nd Annual General Meeting will be held on September 30, 2026...
🔴 Annual Report — 5 September 2026Lincoln Pharmaceuticals informed shareholders that letters with web links to access the FY2025-26 An...
🟡 Board Meeting — 29 August 2026Lincoln Pharmaceuticals announced a final dividend of 18% (₹1.80 per share) payable after approval a...

See all LINCOLN filings →

🔥 Also filed on 24 September 2026

STEELXINDSteel Exchange India LtdAnnouncement 505343Monotype India LtdInsider Trading CARTRADECartrade Tech LtdAnnouncement BLBLIMITEDBLB LtdInsider Trading 530063Yashraj Containeurs LtdAnnouncement KPILKalpataru Projects International LtdAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LINCOLN files new disclosures

Track LINCOLN filings, board meetings, and corporate actions. Free email alerts at 5 PM.